Equities research analysts predict that Moderna, Inc. (NASDAQ:MRNA) will post $6.35 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Moderna’s earnings, with the lowest EPS estimate coming in at $3.27 and the highest estimate coming in at $8.23. Moderna posted earnings per share of ($0.31) in the same quarter last year, which would suggest a positive year-over-year growth rate of 2,148.4%. The company is expected to report its next earnings report on Wednesday, August 4th.
Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for Moderna.
Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 6th. The company reported $2.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.04 by $0.80. Moderna had a net margin of 21.90% and a return on equity of 19.76%. The firm had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $2.48 billion. During the same quarter last year, the company posted ($0.35) earnings per share. The firm’s revenue was up 24112.5% compared to the same quarter last year.
Shares of Moderna stock traded down $2.56 during trading on Friday, hitting $214.44. 115,621 shares of the company’s stock were exchanged, compared to its average volume of 11,188,439. The company has a quick ratio of 1.33, a current ratio of 1.39 and a debt-to-equity ratio of 0.04. The firm’s 50-day simple moving average is $168.85. Moderna has a 52-week low of $54.21 and a 52-week high of $227.71. The company has a market cap of $86.10 billion, a PE ratio of 173.60, a price-to-earnings-growth ratio of 0.76 and a beta of 1.48.
In other Moderna news, insider Juan Andres sold 5,000 shares of Moderna stock in a transaction dated Monday, June 7th. The shares were sold at an average price of $207.04, for a total transaction of $1,035,200.00. Following the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at $1,035,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction dated Monday, March 15th. The stock was sold at an average price of $137.00, for a total transaction of $2,055,000.00. Following the transaction, the president now directly owns 1,614,597 shares in the company, valued at $221,199,789. The disclosure for this sale can be found here. Insiders have sold 2,132,589 shares of company stock worth $280,419,650 over the last 90 days. 19.40% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. Capital Analysts LLC purchased a new position in Moderna during the first quarter worth about $26,000. Catalyst Capital Advisors LLC purchased a new position in Moderna during the fourth quarter worth about $29,000. OLD Second National Bank of Aurora purchased a new position in Moderna during the first quarter worth about $29,000. Sterling Investment Advisors Ltd. raised its stake in Moderna by 380.0% during the first quarter. Sterling Investment Advisors Ltd. now owns 240 shares of the company’s stock worth $31,000 after purchasing an additional 190 shares during the period. Finally, Park Capital Group purchased a new position in Moderna during the fourth quarter worth about $33,000. 51.67% of the stock is currently owned by institutional investors.
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.
Further Reading: What is FinTech?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.